dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

March 30, 2021: Immatics Biotechnologies GmbH

Immatics Announces Full Year 2020 Financial Results and Corporate Update

  • Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients
  • Enrollment across clinical ACTengine® IMA200 trial series continues to scale up
  • Cash and cash equivalents as well as other financial assets of $285 million1 (€232 million) as of December 31, 2020 provide cash reach into 2023

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2020.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2021
March 26, 2021: AC Immune SA
March 30, 2021: CureVac AG

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz